Nymox Pharmaceutical Corp. buy melinda
Start price
02.11.18
/
50%
€1.78
Target price
18.01.19
€2.07
Performance (%)
18.78%
End price
18.01.19
€2.11
Summary
This prediction ended on 18.01.19 with a price of €2.11. The prediction had a final performance of 18.78%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Nymox Pharmaceutical Corp. | - | - | - | - |
| iShares Core DAX® | 1.085% | -0.846% | 12.464% | 58.472% |
| iShares Nasdaq 100 | -1.665% | -3.306% | 1.502% | 84.473% |
| iShares Nikkei 225® | 3.863% | 6.308% | 22.272% | 56.185% |
| iShares S&P 500 | 0.111% | -1.337% | 1.101% | 58.320% |
Comments by melinda for this prediction
In the thread Nymox Pharmaceutical Corp. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 15/11 Publication de résultats
Nymox Pharmaceutical Corp.operates as a biopharmaceutical company, which engages in the research and development on products for the aging population.
Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer.
It operates through the following geographical segments: Canada, United States, and Europe.
The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Nombre d'employés : 2 personnes.
Stopped prediction by melinda for Nymox Pharmaceutical Corp.
Nymox Pharmaceutical Corp.
Start price
Target price
Perf. (%)
€3.70
24.07.16
24.07.16
€4.06
12.08.16
12.08.16
-43.17%
12.08.16
12.08.16
